-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $33

Benzinga·11/11/2026 14:14:02
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $30 to $33.